Immunoassay Testing Remains Superior To Indirect Immunofluorescence For AAV Screening, Study Finds

Rare Disease Advisor (4/24, Lai) reports a study found that “immunoassay testing for antiproteinase 3 (anti-PR3) and antimyeloperoxidase (anti-MPO) retain an advantage against indirect immunofluorescence (IIF) for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) screening.” The results “support the current global consensus that anti-PR3 and anti-MPO immunoassays should remain the preferred screening option for AAV as opposed to screening via IIF.” The study was published in Egyptian Rheumatology and Rehabilitation.